Chris Viehbacher's Compensation: A Reflection of the High Stakes in Pharma Leadership
Chris Viehbacher’s Staggering Payoff In 2022, Chris Viehbacher, former CEO of Biogen, made headlines with his colossal compensation of $30.5 million. This sizable sum—nearly 500 times the average annual salary in the United States—is a testament to the high-stakes nature of leadership in the pharmaceutical industry. Understanding CEO Compensation Viehbacher’s compensation is part of a broader trend toward high executive pay in the biopharmaceutical sector. This trend is driven by the immense value that pharmaceutical companies place on experienced leaders who can drive innovation and revenue growth....